$BNTX News

BioNTech: The Market Is Paying Too Much For An Unproven Pipeline

Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $119

'BioNTech Investor Förtsch Says Founders' Spinout Raises Concerns' - Bloomberg News

Is BioNTech SE (BNTX) A Good Stock To Buy Now?

Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

UBS Upgrades BioNTech to Buy, Raises Price Target to $135

Bernstein Initiates Coverage On BioNTech with Market Perform Rating, Announces Price Target of $96

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech (NasdaqGS:BNTX) Valuation After New Supervisory Board Appointments Focused On Oncology And Commercial Expertise

BioNTech Expands Supervisory Board To Support Oncology Pipeline And Commercial Plans

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech SE 2026 Q1 - Results - Earnings Call Presentation

BioNTech Announces New ADS Repurchase Program

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $158

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $140

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Q1 Earnings Call Highlights

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape